Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Immunohistochemistry Stories

2013-09-11 12:24:27

VENTANA ALK (D5F3) IHC assay will aid in the identification of patients for Pfizer's XALKORI in China TUCSON, Ariz., Sept. 11, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by the Chinese Food and Drug Administration (CFDA) as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI® (crizotinib). The...

2013-09-10 23:24:13

Miraca Life Sciences continues its commitment to the evolution of molecular testing by expanding diagnostic analysis with HER2 testing. IRVING, Texas (PRWEB) September 10, 2013 Miraca Life Sciences is excited to announce the initiation of a new testing protocol that will aid in the management of patients with gastroesophageal adenocarcinoma. This protocol is in response to the 2010 “ToGA” (Trastuzumab in Gastric cancer) clinical trial that demonstrated a clear survival benefit for...

2013-09-09 16:23:53

Highly sensitive test gives researchers a more sophisticated tool to assess PTEN protein expression in cancer cells PLEASANTON, Calif., Sept. 9, 2013 /PRNewswire/ -- As researchers push to develop more customized diagnostics and therapies for solid tumor cancers, they demand increasingly sensitive tests that offer reliable, reproducible analysis. Spring Bioscience, Inc. (Spring) today announced a new addition to its specialized portfolio of valuable antibodies for cancer research...

2013-06-25 19:17:47

Could be reliable and cost-effective diagnostic approach in lung cancer ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and reliable laboratory tests for predictive biomarkers is essential to select appropriate patients for targeted therapy....

2013-06-04 23:24:13

Over the last twelve years, Visiopharm has worked closely with leading Danish and International cancer researchers and pathologists to develop diagnostic software capable of improving and standardizing diagnostic reading, while automating key steps in the diagnostic workflow. This software is now being deployed at central pathology labs across Denmark. Hoersholm, Denmark (PRWEB) June 04, 2013 There is a pressing need to improve and standardize the diagnostic work on cancer in order to...

2013-06-03 10:54:17

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET...

2013-05-21 08:28:18

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 - 4:30 PM. The presentation will...

2013-05-15 20:23:06

-- Data suggest presence of activated progesterone receptors in cells predict anti-progestin efficacy in endometrial and breast cancers; support further evaluation of onapristone FLEMINGTON, N.J., May 15, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at...

2013-03-14 12:27:46

IRVINE, Calif., March 14, 2013 /PRNewswire/ -- GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that it will be launching new antibodies against phosphorylated Histone H2A.X and p53 designed for use with zebrafish samples. (Photo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) The zebrafish is being increasingly utilized as a model organism to study DNA repair. The zebrafish genome contains nearly all of the genes involved in the different DNA...

2013-03-07 04:24:02

NEWCASTLE-UPON-TYNE, England, March 7, 2013 /PRNewswire/ -- Each antibody has been independently assessed* for performance vs. their competitive offerings in the market, thereby enabling confidence in the interpretation of stained slides. The BOND(TM) Ready-to-Use products are optimized to deliver high quality staining on the Leica BOND immunostainer. Products are available in a range of formats to align with customer requirements for efficiency and convenience. (Photo:...